Which pharma will top oncology?

Posted 1 July 2024 AM

A shake-up in the oncology sector is underway, with analysts predicting a change in the top companies by the end of the decade.

Next year the oncology market is expected to be led by MSD, which will pull in US$31.1 billion in 2025, according to KBI Biopharma Senior Market Analyst, Nicolas Schmitz. He used data from a variety of sources to rank pharmas by revenue in oncology.

To see the whole article, please login

Popular

Next big meds: the countdown is on

Company on Aussie hiring spree

Aussie pharma settles class action

Novartis enters Aussie partnership

Latest Jobs

Customer Service Representative

Technical Customer Support Specialist

Finance Analyst

QC Microbiologists

QC Laboratory Assistants

See all...

Pharma in Focus Jobs

Marketing & Communications (1)

Senior Brand Manager - Sydney

Sales & Customer Relations (23)

Clinical & Medical, R&D (13)

Regulatory, Pharmacovigilance & QA (9)

Other (20)

MORE NEWS

Email this article to a friend

From:

Subject

Friend's email

Message to go with the article

Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

Retype password

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.

Skip password for now